Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Acupuncture needles aim to boost IVF success in women with repeated failure

NCT ID NCT07486297

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether acupuncture can increase pregnancy rates in women who have had multiple failed embryo transfers (recurrent implantation failure). 208 women aged 20-40 will receive either real indwelling intradermal needles or placebo non-penetrating needles before their frozen embryo transfer. The main goal is to see if more women achieve a clinical pregnancy with acupuncture.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
acupuncture (indwelling intradermal needles or non-penetrating placebo needles)
What this could lead to
If it works, this could offer a simple, low-risk way to improve pregnancy chances for women who have repeatedly failed embryo transfers.
What could go wrong
This is an early-stage trial with only 208 participants, so results may not apply to everyone. The placebo group uses non-penetrating needles, which may still have a psychological effect, making it hard to prove real benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 208 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos). 2. Age: 20 to 40 years old. 3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET). 4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC). 5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation. Exclusion Criteria: 1. Individuals planning to undergo preimplantation genetic diagnosis (PGD). 2. Recipients of egg donations. 3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms). 4. Patients with known embryo-related factors leading to implantation failure. 5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on). 6. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more). 7. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months. 8. Individuals with untreated hydrosalpinx; 9. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg/m2. 10. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Implantation failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.